首页|凉山州某地HIV-1感染育龄妇女获得性耐药情况及相关因素分析

凉山州某地HIV-1感染育龄妇女获得性耐药情况及相关因素分析

扫码查看
目的 分析凉山地区某县HIV-1感染育龄妇女获得性耐药(ADR)情况及其相关因素.方法 以2023年1-9月在凉山地区某县治疗随访的105例HIV-1感染育龄妇女为研究对象,采集并分离血液标本,将标本用于HIV-1 RNA和HIV-1 DNA定量检测以及HIV-1基因型耐药检测.结果 105例研究对象中,HIV-1 RNA以0~50 copies/mL 为主(69.5%),HIV-1 DNA 以 101~1 000 copies/106 cells 为主(67.6%),HIV-1 亚型以 CRF07_BC 重组型为主(88.6%),初始cART方案以2 NRTIs+1 NNRTIs为主(90.5%).105例研究对象中,21例发生ADR(20.0%),其中HIV-1 RNA基因型耐药检出发生ADR的11例(10.5%),HIV-1 DNA基因型耐药检出发生ADR的10例(9.5%).105例研究对象中,32例(30.5%)出现耐药突变位点.与NNRTIs有关的耐药突变有9例(8.6%),K103KN/N/S是主要耐药突变位点;与NRTIs有关的耐药突变有3例(2.9%),M184MV/MI/V是主要耐药突变位点;与整合酶抑制剂(INSTIs)有关的耐药突变有7例(6.7%),A128T是主要耐药突变位点;11例(10.5%)同时针对NNRTIs和NRTIs出现耐药突变;1例同时针对NNRTIs、NRTIs及INSTIs出现耐药突变;1例同时针对NNRTIs及INSTIs出现耐药突变.无针对PIs的耐药突变出现.经单因素Logistic回归分析显示cART时间、年龄、初始cART方案、HIV-1感染途径及HIV-1亚型与ADR发生无统计学关联.结论 凉山地区某县HIV-1感染育龄妇女ADR发生率与凉山地区总体耐药率接近,但耐药突变位点复杂多样,耐药突变导致的耐药主要以单纯NNRTIs耐药、NRTIs和NNRTIs同时耐药为主,而NNRTIs和NRTIs作为cART的一线用药,在HIV治疗中占据重要地位,因此需加强耐药监测,进一步提升治疗质量.
HIV-1 drug resistance and related factors in women of childbearing age infected with HIV-1 in a county of the Liangshan area
Objective This study aimed to analyze the prevalence of acquired drug resistance(ADR)in HIV-1 infected women of childbearing age in a county of the Liangshan area and identify any relevant factors.Methods From January to September 2023,a total of 105 HIV-1 infected women of childbearing age undergoing treatment in a county of the Liangshan area were recruited for this study.Blood specimens were collected and separated for quantitative detection of HIV-1 RNA and DNA,and HIV-1 genotypic drug resistance testing.Results Among the 105 study subjects,HIV-1 RNA levels were predominantly in the range of 0-50 copies/mL(69.5%).Similarly,HIV-1 DNA levels were mainly between 101-1 000 copies/106 cells(67.6%).The primary HIV-1 subtype was the recombinant form CRF07BC(88.6%).Notably the initial combined antiretroviral therapy(cART)regimen for most participants(90.5%)consisted of two nucleoside reverse transcriptase inhibitors(NRTIs)combined with one non-nucleoside reverse transcriptase inhibitor(NNRTI).The overall prevalence of ADR was 20.0%(21 out of 105 subjects).HIV-1 RNA genotypic drug resistance was detected in 11 cases(10.5%),while HIV-1 DNA genotypic drug resistance was identified in 10 cases(9.5%).A total of 32 drug-resistance mutation sites were observed(mutation rate of 30.5%).Nine cases(8.6%)exhibited resistance mutations of primarily related to NNRTIs.The major resistance mutation site was K103KN/N/S.Three cases(2.9%)had resistance mutations mainly associated with NRTIs.M184MV/MI/V was the primary resistance mutation site observed.Seven cases(6.7%)displayed resistance mutations linked to integrase inhibitors(INSTIs),with A128T being the dominant mutation site.Eleven cases(10.5%)showed resistance mutations against both NNRTIs and NRTIs.One case each displayed resistance mutations against NNRTIs,NRTIs,and INSTIs,and both NNRTIs and INSTIs.Importantly,no resistance mutations were detected against protease inhibitors.Univariate logistic regression analysis revealed no statistically significant correlation between the incidence of ADR and factors like cART duration,age,initial cART regimen,cause of HIV infection,and HIV-1 subtype.Conclusions The prevalence of ADR in HIV-1-infected women of childbearing age within this county of the Liangshan area is comparable to the overall drug resistance rate reported in the wider Liangshan region.However,the mutation sites within drug-resistance are complex and diverse.In this study,drug resistance was primarily driven by mutations related to NNRTIs,both as single mutations and in combination with NRTI mutations.Since NNRTIs are a cornerstone component of first-line cART regimens,these findings highlight the importance of strengthening drug resistance monitoring to ensure optimal antiretroviral therapy outcomes.

HIVwomen of childbearing ageacquired drug resistanceantiretroviral therapy

刘镓鑫、刘梅、宋绍芳、谢芳、杨在琴、耿忠敏、黄永茂、黄富礼、曹汴川

展开 >

西南医科大学附属医院感染病科,四川泸州 646000

西南医科大学附属医院结核病科,四川泸州 646000

西南医科大学附属医院感染与免疫实验室,四川泸州 646000

越西县第一人民医院抗病毒治疗中心,四川凉山 616650

越西县妇幼保健计划生育服务中心,四川凉山 616650

越西县卫生健康局,四川凉山 616650

展开 >

育龄妇女 获得性耐药 艾滋病病毒 抗反转录病毒治疗

中国性病艾滋病防治协会·妇幼泰格关爱及预防母婴传播基金凉山州科技计划资助

PMTCT20220723ZDYF0064

2024

中国艾滋病性病
中国性病艾滋病防治协会

中国艾滋病性病

CSTPCD北大核心
影响因子:1.292
ISSN:1672-5662
年,卷(期):2024.30(6)